$IVST a new report has been published on Innovest
Post# of 74540
(Total Views: 197)
Posted On: 03/12/2018 11:46:16 AM
$IVST a new report has been published on Innovest Global, Inc. (OTC Pink: IVST). Innovest Global, Inc. is a diversified holding company that focuses on acquiring niche, high-growth businesses that are capable of generating significant annual revenue. The company’s planned subsidiaries operate across telehealth, biotech, commercial energy, business-to-business distribution, national call center and auto sales.
The report provides an overview of Innovest Global, Inc., its subsidiaries, financials, industry analysis and more. The content also covers the global outlook for the biotechnology industry.
Global Biotech Industry Forecast to Reach $727.10 Billion By 2025
The fight against the next major outbreak will heavily rely on biotechnology in order to effectively find a treatment or cure. This makes biotech one of the key frontiers against emerging health threats, such as viruses and drug-resistant bacteria.
Without an aggressive effort to research and develop (R&D) treatments to fight some of the largest threats to humanity, we risk reliving deadly periods in history such as the “Black Death.” The pandemic wiped out 50 million people in the 14th century, which equated to 60% of Europe’s population at the time of the plague outbreak.
According to Grand View Research, Inc., the global biotechnology market is forecast to hit $727.10 billion by 2025. The firm notes that the growth will most likely be generated by regenerative medicines and genetics in diagnostics. Grand View further notes that technological advances are helping biotech companies with greater R&D and clinical testing capabilities. Overall, this will help with advancing treatments and research methods.
Innovest Launching New Biotech and Health Sciences Division This Spring, Will Be Headquartered in Los Angeles, CA
Innovest Global, Inc. recently announced that it is preparing to launch a new biotechnology and health sciences division this spring, which will be headquartered in Los Angeles, CA. The new division will be led by world-renowned neuroscientist, Dr. Dwain Morris-Irvin.
Dr. Morris-Irvin received his PhD from the UCLA School of Medicine and Masters in Public Health from UCLA School of Public Health. Furthermore, the distinguished neuroscientist trained at The Wallenberg Neuroscience Center at Lund University in Lund, Sweden.
“Dr. Morris-Irvin is an active participant in many Biotechnology and Health Science endeavors, and is an expert including patent generation in such areas as treatments for Parkinson’s, brain cancer, and even cosmetic application of advanced bioscience,” said Dan Martin, CEO of Innovest Global.
The official Twitter page of Innovest Global, Inc. has recently announced a variety of exciting meetings with potential acquisition targets, business owners, and local congressional representatives. The U.S. Congressman in Innovest’s district in Ohio has recently met with Dan Martin and the Innovest Global team a couple of times over the past month, as they discuss legislative matters and the benefits of the Trump tax cuts. However, this also shows that management continues to have the company on the path to success. You certainly do not hear about any other congressional leaders are visiting Pink Sheet companies. This shows the company is not only on the right track, but also turning heads.
Innovest announced that it has generated revenues of $388,000, through half of the first quarter 2018. This beat management’s estimates by 55% and puts the company well on its way to beating its goal of reporting $500,000 in revenue per quarter.
Management has also noted in recent press releases that the company continues to search for quality acquisitions, as it processes its growing pipeline. Furthermore, Innovest is currently vetting PCAOB auditors to be engaged with the company and assist with auditing the financials. This is in addition to the fact that the company’s corporate counsel is an official OTCQX sponsor, which positions the company to continue pursuing uplisting endeavors that have been laid out in previous press releases.
For more information on Innovest Global, Inc., please visit http://innovestglobal.com and http://spotlightgrowth.com/index.php/2018/03/...s-angeles/
The report provides an overview of Innovest Global, Inc., its subsidiaries, financials, industry analysis and more. The content also covers the global outlook for the biotechnology industry.
Global Biotech Industry Forecast to Reach $727.10 Billion By 2025
The fight against the next major outbreak will heavily rely on biotechnology in order to effectively find a treatment or cure. This makes biotech one of the key frontiers against emerging health threats, such as viruses and drug-resistant bacteria.
Without an aggressive effort to research and develop (R&D) treatments to fight some of the largest threats to humanity, we risk reliving deadly periods in history such as the “Black Death.” The pandemic wiped out 50 million people in the 14th century, which equated to 60% of Europe’s population at the time of the plague outbreak.
According to Grand View Research, Inc., the global biotechnology market is forecast to hit $727.10 billion by 2025. The firm notes that the growth will most likely be generated by regenerative medicines and genetics in diagnostics. Grand View further notes that technological advances are helping biotech companies with greater R&D and clinical testing capabilities. Overall, this will help with advancing treatments and research methods.
Innovest Launching New Biotech and Health Sciences Division This Spring, Will Be Headquartered in Los Angeles, CA
Innovest Global, Inc. recently announced that it is preparing to launch a new biotechnology and health sciences division this spring, which will be headquartered in Los Angeles, CA. The new division will be led by world-renowned neuroscientist, Dr. Dwain Morris-Irvin.
Dr. Morris-Irvin received his PhD from the UCLA School of Medicine and Masters in Public Health from UCLA School of Public Health. Furthermore, the distinguished neuroscientist trained at The Wallenberg Neuroscience Center at Lund University in Lund, Sweden.
“Dr. Morris-Irvin is an active participant in many Biotechnology and Health Science endeavors, and is an expert including patent generation in such areas as treatments for Parkinson’s, brain cancer, and even cosmetic application of advanced bioscience,” said Dan Martin, CEO of Innovest Global.
The official Twitter page of Innovest Global, Inc. has recently announced a variety of exciting meetings with potential acquisition targets, business owners, and local congressional representatives. The U.S. Congressman in Innovest’s district in Ohio has recently met with Dan Martin and the Innovest Global team a couple of times over the past month, as they discuss legislative matters and the benefits of the Trump tax cuts. However, this also shows that management continues to have the company on the path to success. You certainly do not hear about any other congressional leaders are visiting Pink Sheet companies. This shows the company is not only on the right track, but also turning heads.
Innovest announced that it has generated revenues of $388,000, through half of the first quarter 2018. This beat management’s estimates by 55% and puts the company well on its way to beating its goal of reporting $500,000 in revenue per quarter.
Management has also noted in recent press releases that the company continues to search for quality acquisitions, as it processes its growing pipeline. Furthermore, Innovest is currently vetting PCAOB auditors to be engaged with the company and assist with auditing the financials. This is in addition to the fact that the company’s corporate counsel is an official OTCQX sponsor, which positions the company to continue pursuing uplisting endeavors that have been laid out in previous press releases.
For more information on Innovest Global, Inc., please visit http://innovestglobal.com and http://spotlightgrowth.com/index.php/2018/03/...s-angeles/
(0)
(0)Scroll down for more posts ▼